Lessons from natural products chemistry can offer novel approaches for synthetic chemistry in drug discovery

Author(s): Vasilevich NI, Kombarov RV, Genis DV, Kirpichenok MA

Abstract

Drug discovery leading to robust and viable lead candidates’ remains a challenging scientific task, which is the transition from a screening hit to a drug candidate, requires expertise and experience. Natural products and their derivatives have been recognized for many years as a source of therapeutic agents and of structural diversity. However, in addition to their chemical structure diversity and their biodiversity, the development of new technologies has revolutionized the screening of natural products in discovering new drugs. Applying these technologies compensates for the inherent limitations of natural products and offers a unique opportunity to re-establish natural products as a major source for drug discovery. The present article attempts to describe the utilization of compounds derived from natural resources as drug candidates, with a focus on the success of these resources in the process of finding and discovering new and effective drug compounds, an approach commonly referred to as “natural product drug discovery.

Similar Articles

Medicinal plants and phytomedicines

Author(s): Briskin DP

New natural products as new leads for antibacterial drug discovery

Author(s): Brown DG, T Lister, TL May-Dracka

Amazonian plant natural products: perspectives for discovery of new antimalarial drug leads

Author(s): Pohlit AM, Souza Lima RB,Frausin G,Rocha e SilvaLF,Pinto Lopes SC, et al.

Natural products: promising resources for cancer drug discovery

Author(s): Mondal S, Bandyopadhyay S, Ghosh MK, Mukhopadhyay S, Roy S, et al.

Plant antitumor agents

Author(s): Wall ME, MC Wani, CE Cook, KH Palmer, AT McPhail, et al.

Plant antitumor agents

Author(s): Wani MC, Taylor HL, WallME, Coggon P, McPhail AT, et al.

3D-QSAR study of 20 (S)-camptothecin analogs

Author(s): Lu AJ, Zhang ZS, Zheng MY, Zou HJ, Luo XM, et al.

Plants used against cancer

Author(s): Hartwell JL

Plants used against cancer

Author(s): Hartwell JL

Screening plants for antitumor activity

Author(s): Perdue RE Jr, Abbott BJ, Hartwell JL

Antineoplastic components of marine animals

Author(s): Pettit GR, Day JF, Hartwell JL, Wood HB

Studies on Camptothecin

Author(s): Horwitz SB, Chang CK, Grollman AP

Grollman, Antiviral action of camptothecin

Author(s): Horwitz SB, Chang CK, Grollman AP

DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues

Author(s): Hsiang YH, Liu LF, Wall ME, Wani MC, Nicholas AW

Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA

Author(s): Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG

Mechanism of action of camptothecin

Author(s): Liu LF, Desai SD, Li TK, Mao Y, Sun M, et al.

Antitumour drugs impede DNA uncoiling by topoisomerase I

Author(s): Koster DA, Palle K, Bot ES, Bjornsti MA, Dekker NH

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

Author(s): Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, et al.

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

Author(s): ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, et al.

Phase I clinical trial of topotecan and pegylated liposomal doxorubicin

Author(s): Garcia AA, Roman L, Muderspach L, O'meara A, Facio G, et al.

Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan)

Author(s): Giovanella BC, Stehlin JS, Hinz HR, Kozielski AJ, Harris NJ, etal.

A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer

Author(s): Baka S, Ranson M, Lorigan P, Danson S, Linton K, et al.

Phase II trial of oral rubitecan in previously treated pancreatic cancer patients

Author(s): Burris HA, Rivkin S, Reynolds R, Harris J, Wax A, et al.

Anti-apoptotic mechanisms of drug resistance in cancer

Author(s): Wilson TR, Johnston PG, Longley DB